GlassScriptPhysician profile
Logan Walters Edmonds
NPI 1821483298
$2,689.78
in general payments reported to CMS, 2019-2025
34 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $1,438 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.93 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $322.34 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $215.46 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $179.83 | 2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $148.11 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $126.36 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.63 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $103.82 | 2023-2025 | Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $95.88 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $91.33 | 2024-2025 | Airsupra, Farxiga |
| Shield Therapeutics INC | $90.12 | 2024 | |
| Amgen INC. | $88.02 | 2025 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $84.84 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $63.87 | 2024-2025 | |
| Insulet Corporation | $56.65 | 2025 | Omnipod |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.51 | 2023-2025 | |
| Axsome Therapeutics, INC. | $50.48 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $45.92 | 2024 | Loreev Xr |
| Lundbeck LLC | $45.26 | 2023-2024 | Rexulti |
| Ardelyx, INC. | $43.97 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $38.09 | 2024 | |
| Corcept Therapeutics | $34.63 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $28.24 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.06 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $23.82 | 2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $23.09 | 2025 | Watchman Access System |
| Esperion Therapeutics, INC. | $18.74 | 2023 | Nexletol |
| Azurity Pharmaceuticals, INC. | $16.84 | 2025 | Edarbi |
| Merck Sharp & Dohme LLC | $16.31 | 2025 | Lagevrio |
| Astellas Pharma US INC | $15.51 | 2024 | Veozah |
| Sage Therapeutics, LLC | $15.19 | 2025 | Zurzuvae |
| Alnylam Pharmaceuticals INC. | $14.84 | 2025 | Onpattro |
| Amneal Pharmaceuticals LLC | $14.14 | 2024 | Unithroid |
| Currax Pharmaceuticals LLC | $12.95 | 2023 | Nexlizet, Contrave, Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Edmonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.